Cell Genesys, Inc. (CEGE) Combats Prostate Cancer; Publishes Results
According to the American Cancer Society, roughly 218,890 new cases of prostate cancer were diagnosed in the United States in 2007; one in six men will be diagnosed with prostate cancer during his lifetime, though one in 34 will die from it. Still, the latter statistic is little comfort to those afflicted with the disease. Cell Genesys, Inc. (NASDAQ: CEGE) is engaged in fighting the cancer, conducting clinical trials of GVAX immunotherapy for prostate cancer. According to Cell Genesys’ trials completed in 2007, the GVAX cell-based immunotherapy generated antibody responds to an array of antigens known to be associated with…